| Revenue growth | 18% YoY growth; highest ever quarterly revenue. |
|---|---|
| Margins | EBITDA margin improved through operational leverage and business mix. |
| Demand visibility | Positive outlook for CDMO and Exports; TGx expected to bridge gaps. |
| Management confidence | High; citing 14 consecutive quarters of record revenue. |
Growth
Q1FY27 Revenue grew 18% YoY to INR 248 Cr. EBITDA (excl. ESOP) grew 26% to INR 34 Cr; PAT grew 37% to INR 25 Cr.
Outlook
Plant 6 commercialization on track for H1FY27. Target revenue capacity of INR 1,100 Cr once fully operational.
Risks
Trade Generics vertical impacted by discontinuation of codeine-based products. API price volatility remains a monitoring point.
Last quarter's promises, checked
Delivered
- Plant 6 mechanical completion → achieved (H1FY27 launch on track) (= BEAT)
- Revenue growth of 19% YoY for FY26 → delivered 19% (= BEAT)
- Maintain ROCE/ROE above 25% → sustained above 25% (= BEAT)
Partly delivered
- Fill codeine-based revenue loss with alternates → partially filled in Q4 (= PARTIAL)
Earnings Call Transcript filed with BSE, NSE: WINDLAS. Summary written with AI assistance from the document.
Windlas Biotech Ltd: key numbers
- Share price
- ₹1,028.00
- Market cap
- ₹2,158 Cr
- Revenue (annual)
- ₹904.1 Cr
- Net profit (annual)
- ₹66.44 Cr
- P/E (TTM)
- 32.5×Sector 47.4×
- Promoter holding
- 63.31%+1.41% QoQ
- FII holding
- 2.04%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Windlas Biotech Ltd
All →Windlas Biotech Results Update
Windlas Biotech reported Q1 FY27 revenue of Rs 248 crore, an 18% YoY growth. The release highlights an adjusted EBITDA of Rs 34 crore and PAT of Rs 25 crore.
Windlas Biotech Investor Presentation: Key Takeaways
Windlas Biotech reported Q1FY27 revenue of ₹248 Cr (18% YoY). Adjusted EBITDA and PAT grew 26% and 37% respectively, excluding ESOP costs, driven by CDMO expansion.
Windlas Biotech Q1 FY27 Results: Net Profit ₹17.7 Cr, Up 0.0% YoY
Windlas Biotech Ltd reported revenue from operations of ₹248.1 Cr (+18.1% YoY) and net profit of ₹17.7 Cr (+0.0% YoY) for Q1 FY27.
- Key figure
- Net profit ₹17.7 Cr · +0.0% YoY
Windlas Biotech Board Meeting Date
Windlas Biotech Limited has scheduled a board meeting on August 10, 2026, to consider and approve its unaudited standalone financial results for the quarter ending June 30, 2026.
Windlas Biotech Annual General Meeting
Windlas Biotech Ltd held its 25th Annual General Meeting on July 23, 2026. Shareholders approved the financial statements and a final dividend of Rs. 6.30 per share.
Windlas Biotech Annual Report
Windlas Biotech Limited filed its Annual Report for the financial year 2025-26. The report highlights the company's operational performance and growth milestones.